Arno Therapeutics (ARNI) Stock Price, News & Analysis

Company Overview

Arno Therapeutics, Inc. was a biopharmaceutical company focused on developing investigational therapies for cancer and other serious diseases. Its research programs centered on compounds intended to target tumor growth and survival through multiple biological mechanisms.

The company’s historical development pipeline included AR-67, a camptothecin-derived cancer drug candidate, and AR-42, a histone deacetylase inhibitor investigated for potential use in oncology. Arno also evaluated additional preclinical compounds designed to address unmet needs in cancer treatment.

Arno Therapeutics conducted its business primarily through pharmaceutical research and development partnerships, clinical studies, and licensing activities. Publicly available information about the company’s current operations, leadership, geographic activities, and commercial products is limited.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0001
• Volume: N/A
• Average Volume: 8,820 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ARNI
• CIK: 1195116
• Web: www.arnothera.com
• Phone: (503) 598-6659
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A